LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)

Tony Mok, J.L. Pujol, M. Tsuboi, J. Lee, E. Kim, O. Leonov, Jun Zhang, Jiying Duan, C. Lobetti-Bodoni, J.C. Brase, A. Savchenko, P. Garrido Lopez